Arbutus Biopharma Corp - Company Profile
Powered by
All the data and insights you need on Arbutus Biopharma Corp in one report.
- Save hours of research time and resources with
our up-to-date Arbutus Biopharma Corp Strategy Report
- Understand Arbutus Biopharma Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Arbutus Biopharma Corp (Arbutus Biopharma), formerly Tekmira Pharmaceuticals Corp, focuses on the discovery, development, and commercialization of proprietary drugs and drug delivery systems indicated for the treatment of chronic hepatitis B infection (HBV). Its pipeline includes capsid assembly inhibitors: AB-729, PD-L1 Inhibitor and a HBV RNA destabilizer. The company develops product candidates based on its lipid nanoparticle (LNP) delivery technology. Arbutus Biopharma works in partnership and collaboration with Genevant Sciences Inc, Alnylam Pharmaceuticals Inc, Acrotech Biopharma LLC and Gritstone Oncology. The company operates in the US and Canada. Arbutus Biopharma is headquartered in Warminster, Pennsylvania, the US.
Arbutus Biopharma Corp premium industry data and analytics
Products and Services
Products |
---|
Pipeline - |
AB-729 (RNA Interface) |
AB-836 (Capsid Inhibitor) |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Arbutus Biopharma Corp | Dicerna Pharmaceuticals Inc | Silence Therapeutics Plc | SELLAS Life Sciences Group Inc | Adhera Therapeutics Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United Kingdom | United States of America | United States of America |
City | Warminster | Lexington | London | New York | Wake Forest |
State/Province | Pennsylvania | Massachusetts | England | New York | North Carolina |
No. of Employees | 96 | 302 | 116 | 17 | 1 |
Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Frank Torti, M.D. | Chairman | Executive Board | 2018 | 44 |
David C. Hastings | Chief Financial Officer | Senior Management | 2018 | 61 |
Mike McElhaugh | Chief Executive Officer - Interim; Chief Operating Officer; President - Interim | Senior Management | 2024 | - |
Christopher Naftzger | Chief Compliance Officer; General Counsel | Senior Management | 2023 | - |
Karen Sims | Chief Medical Officer | Senior Management | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward